Foghorn Therapeutics Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Foghorn Therapeutics.
Earnings growth rate
EPS growth rate
|Biotechs earnings growth||22.4%|
|Revenue growth rate||50.0%|
|Future return on equity||n/a|
|Last updated||09 May 2023|
Recent future growth updates
Foghorn Therapeutics: Selling For Less Than Cash ValueOct 10
Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286Aug 23
Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49MAug 09
Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals OpportunityJun 02
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash WiselyApr 13
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?Feb 27
Earnings and Revenue Growth Forecasts
|Date||Revenue||Earnings||Free Cash Flow||Cash from Op||Avg. No. Analysts|
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FHTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FHTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FHTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FHTX's revenue (50% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: FHTX's revenue (50% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FHTX's Return on Equity is forecast to be high in 3 years time